Fig. 2From: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugsdropouts due to AEs and change in MMD versus placebo in chronic migraine patients. The size of the circle corresponds to the number of patients that were treated with the prophylactic agent across all RCTs. top: topiramate; onabot: onabotulinumtoxinA; CGRP: CGRP MAb; RCT: randomised controlled trial; MMD: monthly migraine daysBack to article page